Lung Cancer, Conjugates Emerge As Key Asia Company Themes
Executive Summary
Among Asia Pacific pharma companies presenting new clinical data on their oncology pipelines at ASCO, lung and urothelial cancer and antibody-drug conjugates emerge as stand-out themes.
You may also be interested in...
ADC Therapeutics Raises $76m To Keep ADC Development Momentum Going
The company extended its series E financing to $276m to keep its two lead ADC candidates moving toward pivotal data and BLA filings, including a planned filing for ADCT-402 late next year. The funding news comes as the ADC field moves into the spotlight.
So Far, Still So Good For Seattle Genetics/Astellas’ Bladder Cancer ADC
Updated data from the Phase II EV-201 study of Seattle Genetics/Astellas Pharma’s novel ADC are strong enough to warrant accelerated approval, its investigators claim. An accelerated submission to the US FDA is due later this year.
Can Takeda's Alunbrig Take On Roche's Alecensa In First-Line ALK-Positive Lung Cancer?
Takeda's Phase III win over Pfizer's Xalkori leaves oncologists cheering, but hankering for a head-to-head study against Alecensa, which is becoming the standard of care in the US for first-line ALK+ NSCLC.